What's in CHU de Quebec-Universite Laval's pipeline?

CHU de Quebec-Universite Laval has 14 drugs in our index: 11 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with CHU de Quebec-Universite Laval's portfolio?

Top competitors by shared drug class: Sanofi, Massachusetts General Hospital, Merck Sharp & Dohme LLC, Pfizer, Pfizer's Upjohn has merged with Mylan to form Viatris Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/chu-de-quebec-universite-laval.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

CHU de Quebec-Universite Laval — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CHU de Quebec-Universite Laval pipeline: 11 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

11 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Generic latanoprost	Generic latanoprost	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)	Ophthalmology
Acetylsalicylic Acid 80 mg	Acetylsalicylic Acid 80 mg	marketed
PrEP using Truvada	PrEP using Truvada	marketed
Anti-TNF suspended perioperatively	Anti-TNF suspended perioperatively	marketed
Anti-TNFα continued perioperatively	Anti-TNFα continued perioperatively	marketed
4CMenb	4CMenb	marketed	Conjugate vaccine	Neisseria meningitidis serogroup B polysaccharide capsule	Immunology / Infectious Disease
Vitamin D chewable tablet supplementation	Vitamin D chewable tablet supplementation	marketed	Vitamin supplement	Vitamin D receptor (VDR)	Nutritional supplementation / Bone health
SASS	SASS	marketed			Other
Brand-name latanoprost	Brand-name latanoprost	marketed	Prostaglandin F analog	FP prostaglandin receptor	Ophthalmology
Monthly antibiotic	Monthly antibiotic	marketed	Antibiotic (long-acting formulation)		Infectious Disease
Vitamin D pill supplementation	Vitamin D pill supplementation	marketed	Vitamin/nutritional supplement	Vitamin D receptor (VDR)	Nutritional supplementation / Bone health / Immunology
Enzalutamide capsule	Enzalutamide capsule	phase 3	Androgen receptor antagonist	Androgen receptor (AR)	Oncology

Therapeutic area mix

Ophthalmology · 2
Immunology / Infectious Disease · 1
Infectious Disease · 1
Nutritional supplementation / Bone health · 1
Nutritional supplementation / Bone health / Immunology · 1
Oncology · 1
Other · 1
Gastroenterology · 1
Urology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Sanofi · 3 shared drug classes
Massachusetts General Hospital · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes
Pfizer · 2 shared drug classes
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 2 shared drug classes
Association for Innovation and Biomedical Research on Light and Image · 1 shared drug class
Allergan · 1 shared drug class
Aga Khan University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for CHU de Quebec-Universite Laval:

Cite this brief

Drug Landscape (2026). CHU de Quebec-Universite Laval — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/chu-de-quebec-universite-laval. Accessed 2026-05-16.